Showing results (161-170 of 293) with videos related to
Sort By:
Pageof 30
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 30, 2013
Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancerScott T Tagawa, Matthew I Milowsky, Michael Morris, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2022
Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nanogenerator Actinium-225-LintuzumabTodd L Rosenblat, Michael R McDevitt, Jorge A Carrasquillo, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2010
Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I studyJason A Konner, Katherine M Bell-McGuinn, Paul Sabbatini, et al.European Journal of Nuclear Medicine and Molecular Imaging|May 9, 2013
Phase I pharmacokinetic and biodistribution study with escalating doses of ²²³Ra-dichloride in men with castration-resistant metastatic prostate cancerJorge A Carrasquillo, Joseph A O'Donoghue, Neeta Pandit-Taskar, et al.Cancer|May 2, 2013
Posterior reversible encephalopathy syndrome in neuroblastoma patients receiving anti-GD2 3F8 monoclonal antibodyBrian H Kushner, Shakeel Modak, Ellen M Basu, et al.Cancer|September 7, 2012
Ifosfamide, carboplatin, and etoposide for neuroblastoma: a high-dose salvage regimen and review of the literatureBrian H Kushner, Shakeel Modak, Kim Kramer, et al.Journal of Hematology & Oncology|November 27, 2025
Naxitamab plus stepped-up dosing of granulocyte-macrophage colony-stimulating factor for primary refractory high-risk neuroblastoma: results of a phase I/II trialBrian H Kushner, Shakeel Modak, Audrey Mauguen, et al.JAMA Oncology|October 17, 2018
Humanized 3F8 Anti-GD2 Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma: A Phase 1 Clinical TrialBrian H Kushner, Irene Y Cheung, Shakeel Modak, et al.International Journal of Radiation Oncology, Biology, Physics|September 6, 2017
Renal Function Outcomes of High-risk Neuroblastoma Patients Undergoing Radiation TherapyThomas H Beckham, Dana L Casey, Michael P LaQuaglia, et al.Pediatric Blood & Cancer|June 24, 2025
Pulmonary Toxicity Associated With Concurrent Lorlatinib and Anti-GD2 Monoclonal Antibody Therapy in Patients With NeuroblastomaWei Wei, Maggie Eidson Fader, Brian H Kushner, et al.Pageof 30